ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0916

UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway

Ahmed Eldaboush1, Darae Kang2 and Victoria Werth3, 1Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Potomac, MD, 3University of Pennsylvania, Wynnewood, PA

Meeting: ACR Convergence 2025

Keywords: Cell-signalling molecules, Dendritic cells, dermatomyositis, Inflammation, interferon

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0916–0933) Innate Immunity Poster

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Extracellular vesicles (EVs) are cell-derived nanoparticles that mediate cell-cell communication. EVs are implicated in photosensitive autoimmune diseases like dermatomyositis (DM) and systemic lupus (SLE), where UVB radiation can trigger systemic flares. Given UVB’s limited dermal penetration, we hypothesize that keratinocyte-derived EVs (KEVs) mediate UVB inflammation via relaying proinflammatory signals from keratinocytes (KCs) to dermal immune cells. Our prior work showed KEVs elicit inflammation in healthy control (HC) PBMCs, but specific immune cell targets remain undefined. This study identifies immune cell subsets responsive to KEVs.

Methods: HaCaT KCs were pretreated ±1 ng/mL IFN-β for 24h (to mimic DM skin), then irradiated with 0 or 75 mJ/cm² UVB and cultured overnight in EV-free media. KEVs were isolated by ultracentrifugation, resuspended in PBS, and incubated overnight with HC PBMCs. Cells were analyzed by flow cytometry.

Results: EVs from UVB-irradiated KCs (UVB-KEVs) significantly induced IFNβ compared to sham-KEVs in conventional dendritic cells (cDCs) [p=0.002], monocyte-derived dendritic cells (MoDCs) [p=0.039], macrophages [p=0.019], CD4⁺ T cells [p=0.036], CD8⁺ T cells [p=0.015], and CD19⁺ B cells [p=0.036]. A similar trend was observed in natural killer cells (NKs) [p=0.09] and plasmacytoid dendritic cells (pDCs) [p=0.149], though not significant. Notably, only EVs from IFNβ-pretreated irradiated KCs (IFNβ-KEVs) significantly stimulated IFNβ in pDCs [p=0.015] and NKs [p=0.007]. UVB-KEVs also induced IFNγ in MoDCs [p=0.034], macrophages [p=0.005], CD8⁺ T cells [p=0.047], and B cells [p=0.039], with non-significant increases in NKs [p=0.2], pDCs [p=0.06], and CD4⁺ T cells [p=0.06]. However, only IFNβ-KEVs significantly induced IFNγ in pDCs [p=0.001]. UVB-KEVs increased p-NFκB in NKs [p=0.033], CD4⁺ T cells [p=0.021], CD8⁺ T cells [p=0.029], and B cells [p=0.031], with a trend in pDCs [p=0.052]. UVB-KEVs significantly upregulated p-STING in NKs [p=0.0008], pDCs [p=0.006], MoDCs [p=0.0009], macrophages [p=0.0008], CD4⁺ T cells [p=0.017], CD8⁺ T cells [p=0.019], and B cells [p=0.01], with a similar but non-significant trend in cDCs [p=0.12]. However, IFNβ-KEVs significantly increased p-STING in cDCs [p=0.03] and more than UVB-KEVs [p=0.043]. p-STING activation was highest in macrophages and MoDCs. IFNγ was highest in pDCs (only with IFNβ-KEVs); IFNβ was most induced in cDCs and pDCs (again only by IFNβ-KEVs). IFNβ-KEVs uniquely induced both IFNβ and IFNγ in pDCs. Of note, cDCs were previously found to be enriched in DM skin of antimalarial non-responders and express high IFNβ and p-STING, and blood pDCs and cDCs in DM patients secreted more IFNβ than HCs, and pDCs are enriched in DM skin, producing high IFNβ and IFNγ.

Conclusion: UVB-KEVs trigger type I IFN production and activate STING, both upregulated in DM and SLE. Responses were more prominent in innate immune cells. IFNβ-KEVs distinctively activated cDC p-STING and drove pDC IFNβ and IFNγ, both critical in DM/SLE pathogenesis. This suggests a mechanism by which UVB triggers systemic inflammation via KEVs. Ongoing studies aim to block KEV release, dissect their cargo, and mitigate their proinflammatory effects.


Disclosures: A. Eldaboush: None; D. Kang: None; V. Werth: AbbVie/Abbott, 2, Amgen, 2, 5, Anaptysbio, 2, Argenx, 2, 5, AstraZeneca, 2, 5, Biogen, 2, 5, Boehringer-Ingelheim, 2, Bristol-Myers Squibb(BMS), 2, Cabaletta Bio, 2, Calyx, 2, CSL Behring, 5, Cugene, 2, Eli Lilly, 2, EMD Serona, 2, 2, Evommune, 2, Gilead, 2, 5, GlaxoSmithKlein(GSK), 2, Horizon, 5, Immunovant, 2, Janssen, 2, Kwoya Kirin, 2, Merck/MSD, 2, Novartis, 2, Nuvig, 2, Pfizer, 2, 5, Regeneron, 2, 5, Roche, 2, Rome Pharmaceuticals, 5, Sanofi, 2, Takeda, 2, UCB, 2, 2, Ventus, 2, Viela, 5.

To cite this abstract in AMA style:

Eldaboush A, Kang D, Werth V. UVB-Irradiated Keratinocyte Extracellular Vesicles Trigger Innate Immune Activation via Type I Interferons and STING Pathway [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/uvb-irradiated-keratinocyte-extracellular-vesicles-trigger-innate-immune-activation-via-type-i-interferons-and-sting-pathway/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/uvb-irradiated-keratinocyte-extracellular-vesicles-trigger-innate-immune-activation-via-type-i-interferons-and-sting-pathway/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology